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Background: Although combined chemotherapy has increased survival rates among children with cancer, such treatments can induce sensorineural hearing loss. Therefore, we aimed to identify risk factors for hearing impairments in patients with childhood cancer.
Methods: Audiograms were obtained from 115 patients with childhood cancer and survivors (age ＜20 years). Pure tone audiometry (PTA) was performed at octave intervals within the range of 250-8000 Hz. We evaluated clinical risk factors associated with hearing impairments. Hearing loss was evaluated based on the maximal decibel (dB) loss in any frequency for each ear (RA max or LA max ) and weighted mean dB loss for specific frequencies (RA avg or LA avg ).
Results: Forty percent of patients (N=46) exhibited hearing loss ＞20 dB based on the weighted mean value in either ear. Severe hearing impairments were observed in 56% of patients with brain tumors. Although cisplatin or vinca alkaloids were significant risk factors for hearing impairment, the use of both cisplatin and vinca alkaloids exhibited the highest odds ratio for hearing impairment (P＜0.001, ＜0.001 for R/LAmax; P=0.099, 0.039 for R/LA avg ). Multivariate analysis revealed that the use of both cisplatin and vinca alkaloids was an independent risk factor for hearing impairment based on RA max , LA max , and LAavg (P＜0.001, ＜0.001, 0.039, respectively).
Conclusion:
Our findings indicate that cisplatin and vinca alkaloids exert an additive effect on the risk of hearing impairment in survivors of childhood cancer. Further prospective studies are thus required to determine the most effective chemotherapeutic regimen for reducing ototoxicity.
Introduction
Over the past twenty years, survival rates for children with malignant tumors have increased due to the advance of more effective treatments such as combined chemotherapy, as well as improvements in diagnostic methods, surgical techniques, and radiation therapy [1] . However, children with malignant tumors are also exposed to various side effects of chemotherapeutic treatmentwhich vary based on the type of cancer, treatment modalities, chemotherapeutic agents, and age at diagnosiswith more than 60% of survivors experiencing late-onset effects [2, 3] . Curative chemotherapeutic treatments for childhood cancer involving agents such as cisplatin induce sensorineural hearing loss following treatment in up to 85% of patients [1, 4] .
Hearing impairment is one of the most common adverse effects in patients with childhood cancer and survivors [5] , and typically occurs due to ototoxic reactions affecting components of the auditory and vestibular system in the inner ear. Generally, hearing loss is bilateral, irreversible, associated with tinnitus, and begins with the loss of the ability to perceive high-frequency auditory stimuli [1, 5] .
Hearing loss affects various aspects of child development and may result in psychosocial problems as well as delayed development of speech and language; poor educational achievement; and impairments in communication, social interaction, and overall quality of life [2] .
There are various risk factors for hearing impairments in survivors of cancer. Drugs such as antineoplastic agents, aminoglycosides, nonsteroidal anti-inflammatory drugs, antibiotics, diuretics, and anti-hypertensive agents have been associated with hearing impairments and ototoxicity leading to hearing loss [6] . Moreover, chemotherapeutic agents such as doxorubicin, vincristine, cyclophosphamide, gemcitabine, and oxaliplatin are ototoxic [5, 6] . Platinum agents such as cisplatin and carboplatin generate the most severe auditory symptoms, including tinnitus and changes in auditory sensitivity [5] [6] [7] [8] . Radiotherapy, which accelerates the destruction of tumor cells via ionizing radiation beams, can also damage the auditory organs and related brain structures. Hearing loss is most common during radiotherapy for tumors of the head and neck [9, 10] . Previous studies have reported that, when cranial radiotherapy is utilized as the only treatment modality, ototoxicity occurs only when the dosage exceeds 32 Gray (Gy) in cochlear structures [2] .
However, combined chemotherapy and radiation cause worse ototoxicity than either one alone. Nevertheless radiation therapy is limited to most of brain tumors.
In the present study, we aimed to investigate hearing impairments in patients with childhood cancer and survivors according to clinical risk factors such as the type of cancer, classes of chemotherapeutic agents, and other treatment modalities utilized, based on standard medical practices in Korea. Audiograms were recommended for the survivors based on treatment type and medical history. Follow-up procedures and schedules were developed in accordance with Korean standards and institutional guidelines, as described in previous reports [11, 12] . Consent to perform an audiogram was 
Materials and Methods

1) Study population
2) Audiometry
Pure-tone audiometry (PTA) was performed at octave in- pairments were observed in 56% of patients with brain tumors.
3) Clinical risk factors for maximal dB loss
Cranial radiation ＞5,000 cGy was identified as a significant risk factor for RA max but not for LA max (P=0.011, 0.088, respectively) ( Fig. 1A-3 and 4 ).
6) Association between diagnosis and severity of hearing impairment
Maximal dB loss ＞60 dB was observed in more than 50% of patients with brain/other solid tumors (RAmax, P＜ 0.001; LA max , P＜0.001, by linear by linear association, respectively; Fig. 1B-1 and 2) .
7) Multivariate analysis
For RA max ＞60 dB and LA max ＞60 dB, the use of cisplatin and vinca alkaloids was a significant risk factor for hearing impairment, with odds ratios of 65.21 (P=0.001) and
147.4 (P=0.001), respectively ( [13, 14] . However, the rate of hearing impairment in the present study was significantly higher, as hearing loss was observed in over 40% of included patients.
A previous study regarding cisplatin-induced hearing loss reported that 64% of the 55 included patients who had received cisplatin treatment developed hearing impairment, in accordance with rates of 63.5-67.8% observed in the present study [15] . However, Chang et al. reported that hearing loss occurred in 52.2% of included patients who had undergone treatment with cisplatin (N=35/67) [16] , which is lower than those showed in present study. Nonetheless, our study included only 11 patients who had undergone treatment with cisplatin only, which may have resulted in this discrepancy. Among users of both cisplatin and vinca alkaloids, 90.4% exhibited hearing loss in each ear, which significantly affected the proportion of cisplatin users exhibiting hearing loss in our cohort. In addition, inconsistencies in the reported rates of hearing impairment among studies may be due to differences in the combination of treatment agents, age, diagnosis, use of radiotherapy, cumulative doses, and other factors [17] .
Previous studies have further reported that the incidence of platinum-related hearing impairment increases along with increases in cumulative dose [17] . Different dosing formulas, such as dose per kilogram of bodyweight or body surface area, may thus influence these effects. Moreover, research has indicated that bolus injections of chemo-therapeutic agents are more ototoxic than doses provided over a longer duration [17] . Cisplatin ototoxicity manifests
as mild yet permanent bilateral hearing loss, affecting 10-25% of adults and 26-90% of children [18] . In our study, [20] . In our study, vincristine was identified as a significant factor for hearing impairment. While use of either cisplatin or vincristine alone was a risk factor for hearing impairment, the use of both chemotherapeutic agents significantly increased the risk of hearing impairment. To our knowledge, the present study is the first to report an additive effect of cisplatin and vinca alkaloids on the risk for hearing impairment in survivors of childhood cancer. In our study, vincristine combined with cisplatin may potentiate neurologic damage in children with brain tumors or sarcoma.
Our findings also indicated that treatment with actinomycin or antimetabolite served as a favorable factor.
However, such findings do not indicate that these agents exert protective effects against hearing damage, but instead reflect the close association between chemotherapeutic agents and the treatment regimen for specific diagnoses.
Actinomycin is typically used in combination with vincristine, and cyclophosphamide. In contrast, cisplatin-contain-ing regimens usually exclude actinomycin.
In our study, radiation therapy alone was not identified as a significance risk factor, although the risk of hearing loss increased with the addition of cisplatin or vinca alkaloids. Radiation to the cochlea can lead to sensorineural hearing impairment [1] , as histopathologic changes due to radiation therapy often lead to inner ear damage [21] . To reduce late toxicity, treatment should aimed to reduce the volume of normal tissue exposed to radiation [22] .
Diagnosis alone was also not identified as a significant risk factor, likely due to the application of specific treatment modalities and regimens for specific diagnoses. For example, cisplatin is more frequently used in the treatment of brain tumors, neuroblastoma, gynecological cancer, germ cell tumors, and sarcoma than in that for other tumor types [23] . Our findings suggest that the treatment regimen should be modified in patients at risk for severe ototoxicity. While our results indicate that simultaneous use of vincristine and cisplatin should be avoided, further studies are required to determine whether this approach effectively reduces ototoxicity without affecting mortality.
The present study possesses several limitations of note.
First, this study was a retrospective analysis of a heterogeneous study population based on diagnosis and involved only a small number of survivors who had completed audiometry assessments. Moreover, we did not perform long-term follow-up assessments to determine whether further impairments or improvements in hearing loss had occurred. In addition, we were unable to examine the influence of age on hearing impairment due to the limited number of patients. Also, we did not examine the effect of cumulative doses of these agents on hearing impairment.
Nonetheless, our findings indicate that cisplatin and vinca alkaloids exert an additive effect on the risk of hearing impairment when they were used in combination in survivors of childhood cancer. Further prospective studies are thus required to determine the most effective chemotherapeutic regimen for reducing ototoxicity.
